CLASSYS Inc. (KOSDAQ:214150)
55,300
+200 (0.36%)
At close: Dec 5, 2025
CLASSYS Revenue
CLASSYS had revenue of 83.00B KRW in the quarter ending September 30, 2025, with 39.69% growth. This brings the company's revenue in the last twelve months to 317.80B, up 47.44% year-over-year. In the year 2024, CLASSYS had annual revenue of 242.94B with 34.87% growth.
Revenue (ttm)
317.80B
Revenue Growth
+47.44%
P/S Ratio
11.37
Revenue / Employee
806.59M
Employees
394
Market Cap
3.61T
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 242.94B | 62.82B | 34.87% |
| Dec 31, 2023 | 180.12B | 38.32B | 27.02% |
| Dec 31, 2022 | 141.80B | 41.21B | 40.96% |
| Dec 31, 2021 | 100.60B | 24.14B | 31.57% |
| Dec 31, 2020 | 76.46B | -4.67B | -5.76% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2014 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Samsung Biologics | 5.50T |
| Celltrion | 3.90T |
| Yuhan | 2.14T |
| Hanmi Pharm. | 1.47T |
| SK Biopharmaceuticals | 675.41B |
| Sam Chun Dang Pharm. | 220.74B |
| ALTEOGEN | 202.18B |
| LigaChem Biosciences | 159.27B |